Karyopharm (NASDAQ: KPTI) gives 2025 revenue, cash and runway update

Rhea-AI Filing Summary

Karyopharm Therapeutics released preliminary, unaudited 2025 results, expecting total revenue of approximately $145 million for the year, including license and royalty income. For the quarter ended December 31, 2025, it anticipates total revenue of about $33 million.

The company expects U.S. XPOVIO net product revenue of roughly $115 million for 2025, including about $32 million in the fourth quarter. Karyopharm also projects cash, cash equivalents, restricted cash and investments of around $64 million as of December 31, 2025, and believes its existing liquidity, together with expected XPOVIO sales and license revenue, will fund planned operations into the second quarter of 2026.

Insights

Biopharma earnings and liquidity analyst

Karyopharm guides to 2025 revenue of $145M and liquidity into Q2 2026.

Karyopharm Therapeutics expects 2025 total revenue of about $145 million, with U.S. XPOVIO net product revenue of roughly $115 million. For the quarter ended December 31, 2025, it anticipates total revenue of about $33 million and U.S. XPOVIO net product revenue of around $32 million, showing that most revenue comes from its core product.

The company estimates cash, cash equivalents, restricted cash and investments of about $64 million as of December 31, 2025, and states that this liquidity, together with expected XPOVIO sales and license revenue, should fund planned operations into the second quarter of 2026. That wording highlights a relatively short funding runway, which places importance on future revenue, partnering, or financing actions.

All figures are described as preliminary and unaudited, based on management estimates, and the independent auditor has not reviewed them. Final numbers will depend on completion of financial closing procedures and the formal year-end reporting process.

false000150380200015038022026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 12, 2026

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36167				26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)				(IRS Employer Identification No.)
85 Wells Avenue, 2nd Floor Newton, Massachusetts				02459
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced its preliminary unaudited total revenue and U.S. XPOVIO® (selinexor) net product revenue estimates for the fourth quarter and full year ended December 31, 2025 announced its preliminary unaudited cash, cash equivalents, restricted cash and investments as of December 31, 2025, and outlined its 2025 achievements and 2026 objectives. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

Based on preliminary unaudited financial information, the Company expects to report total revenue, which includes license and royalty revenue from partners, of approximately $33 million for the quarter ended December 31, 2025 and approximately $145 million for the year ended December 31, 2025, and expects to report U.S. XPOVIO net product revenue of approximately $32 million for the quarter ended December 31, 2025 and approximately $115 million for the year ended December 31, 2025. The Company also expects to report that its cash, cash equivalents, restricted cash and investments as of December 31, 2025 were approximately $64 million. The Company expects its existing liquidity, including the revenue it expects to generate from XPOVIO net product sales and its license agreements, will be sufficient to fund its planned operations into the second quarter of 2026.

The Company’s total revenue, U.S. XPOVIO net product revenue and cash figures are preliminary and unaudited, represent management’s estimate as of the date of this report and are subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company’s total revenue, U.S. XPOVIO net product revenue and cash figures.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release issued by Karyopharm Therapeutics Inc. on January 12, 2026
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KARYOPHARM THERAPEUTICS INC.
Date: January 12, 2026				By:		/s/ Michael Mano
						Michael Mano
						Executive Vice President, Chief Legal Officer and Secretary

FAQ

What 2025 total revenue is Karyopharm Therapeutics (KPTI) estimating?

Karyopharm expects to report preliminary, unaudited total revenue of approximately $145 million for the year ended December 31, 2025, including license and royalty revenue from partners.

How much U.S. XPOVIO net product revenue did Karyopharm (KPTI) estimate for 2025?

The company estimates preliminary U.S. XPOVIO net product revenue of approximately $115 million for the full year 2025, with about $32 million in the fourth quarter.

What are Karyopharm’s (KPTI) estimated year-end 2025 cash and investments?

Karyopharm expects to report approximately $64 million in cash, cash equivalents, restricted cash and investments as of December 31, 2025, based on preliminary unaudited information.

How long does Karyopharm (KPTI) expect its liquidity to fund operations?

The company believes its existing liquidity, together with expected XPOVIO net product sales and license agreement revenue, will be sufficient to fund planned operations into the second quarter of 2026.

Are Karyopharm’s reported 2025 figures final and audited?

No. The total revenue, U.S. XPOVIO net product revenue and cash figures are described as preliminary and unaudited, based on management’s estimates, and the independent registered public accounting firm has not audited or reviewed them.

What period does Karyopharm’s preliminary fourth-quarter 2025 data cover?

The preliminary fourth-quarter figures, including about $33 million of total revenue and $32 million of U.S. XPOVIO net product revenue, cover the quarter ended December 31, 2025.